文献速递前列腺癌

将前列腺特异性膜抗原正电子发射断层扫描纳入新诊断或生化复发前列腺癌男性的管理决策

Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.
PubMed 文献 · Eur Urol · 2022-11-18

本文为叙述性综述,检索MEDLINE与Scopus上关于68Ga-PSMA PET/CT分期与再分期的荟萃分析、综述和原始研究。研究提示PSMA靶向影像在初诊和复发前列腺癌中优于传统影像,但存在临床相关局限;结论指出缺乏具有临床意义终点的III期临床试验。

要点

  • PSMA靶向影像在初诊和复发前列腺癌中表现优于传统影像,但存在若干临床相关局限。
  • 高危病例治疗前68Ga-PSMA PET/CT较常规实践可更准确分期,并发现部分原本未知的转移灶。
  • 生化复发前列腺癌中PSMA PET较传统影像敏感性及特异性更高,可能检出大部分隐匿病变。

核心结论

  • PSMA诊断研究数据凸显PSMA PET在初诊和复发前列腺癌中的准确性及临床应用。
  • 尽管本综述及现有证据可能带来转移灶定向治疗优越性的印象,但具有临床意义终点的III期临床试验的根本缺乏尚待确定。

研究设计与样本

  • 叙述性综述,通过MEDLINE(经PubMed)和Scopus进行文献检索。
  • 检索策略纳入关于68Ga-PSMA PET/CT分期与再分期的荟萃分析、综述和原始研究。

主要发现

  • 比较PSMA靶向影像与传统影像的研究提示PSMA靶向影像在初诊和复发前列腺癌中表现更优,但存在若干临床相关局限。
  • 高危病例治疗前68Ga-PSMA PET/CT较常规实践可更准确进行前列腺癌分期,并识别出若干原本未知的转移灶。
  • 生化复发前列腺癌中,PSMA PET可较传统影像以更高敏感性和特异性揭示复发部位,可能检出大部分隐匿病变。

临床怎么用

  • 本综述旨在帮助提供者应用最新且相关文献以确定哪些患者真正为寡转移性疾病。
  • 本综述旨在帮助提供者应用最新且相关文献以确定在生化复发背景下谁最可能从局部巩固治疗中获得有意义的缓解。

局限性

  • PSMA靶向影像在初诊和复发前列腺癌中表现更优,但存在若干临床相关局限。
  • 具有临床意义终点的III期临床试验的根本缺乏尚待确定。
  • 关于生化复发前列腺癌如何最佳利用该新技术指导癌症治疗,临床试验结果较为有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Prostate-specific membrane antigen (PSMA) is a promising molecular target for prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to PCA in the primary and recurrent settings. OBJECTIVE: To summarize available data and recommendations regarding the use of PSMA in newly diagnosed and recurrent PCa via a narrative review. EVIDENCE ACQUISITION: A literature review was conducted using MEDLINE (via PubMed) and Scopus. The search strategy included meta-analyses, reviews, and original studies on staging and restaging with 68Ga-PSMA positron emission tomography (PET)/computed tomography (CT). EVIDENCE SYNTHESIS: Studies comparing PSMA-targeted imaging and conventional imaging suggest superior performance of PSMA-targeted imaging in primary and recurrent PCa, albeit with several clinically relevant limitations. Pretreatment 68Ga-PSMA PET/CT allowed more accurate PCa staging in compared to routine practice for high-risk cases, and identified a number of otherwise unknown metastatic lesions. In biochemically recurrent PCa, PSMA PET can reveal sites of recurrence with greater sensitivity and specificity than conventional imaging, potentially detecting a major proportion of occult disease. This review will help providers in applying the most up-to-date and relevant literature to (1) determine which patients truly have oligometastatic disease and (2) ascertain who is most likely to experience a meaningful response to local consolidation in the biochemical recurrence setting. CONCLUSIONS: Data on PSMA diagnostic studies in primary and recurrent PCa highlight the accuracy and clinical application of PSMA PET. While this review and the evidence to date might lead to a perception of superiority in metastasis directed therapy, fundamental lack of phase III clinical trials with clinically meaningful outcomes are yet to be determined. PATIENT SUMMARY: PSMA (prostate-specific membrane antigen) scans have shown great promise for initial evaluation of prostate cancer (PCa) and in detection of PCa recurrence. The benefits are more apparent for initial staging of PCa. There are more limited clinical trial results for PCa recurrence on how best to use this new technique to guide cancer treatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bukavina L, Luckenbaugh AN, Hofman MS, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol. 2022. PMID: 36404204. doi:10.1016/j.eururo.2022.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。